Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Interleukin-1 beta Human ELISA

  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:IL-1ß, Catabolin
Please select your region to see available products and prices.
Cat. No. Size Price


New RD194559200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Saliva

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

1.25 – 80 pg/ml

Limit of Detection

0.4 pg/ml

Intra-assay (Within-Run)

CV = 3.5 %

Inter-assay (Run-to-Run)

CV = 6.0 %

Spiking Recovery

Serum: 83 %
Saliva: 104 %

Dilutation Linearity

Serum: 102 %
Saliva: 96 %

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures IL-1 Beta in serum, plasma (EDTA, heparin, citrate) and saliva
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Animal studies, Cytokines and chemokines and related molecules, Oncology

Summary

IL-1 Beta is a polypeptide cytokine and represents one of the most important mediators of inflammation and host responses to infections. This protein is a member of the interleukin-1 cytokine family, which is closely linked to the innate immune response. Mature form of IL-1 beta has molecular weight of 17.5 kDa and exists in monomeric form. Expression of the gene that encodes IL-1 beta is induced by various proinflammatory stimuli such as bacterial and viral products, other cytokines, cellular injury, monosodium urate crystals and hypoxia. IL-1 beta is produced by many cell types of both the peripheral and central immune system, including lymphocytes and monocytes. The synthesis and release of IL-1 Beta is tightly regulated. IL-1 beta is secreted only upon inflammatory signals and is not present in homeostatic conditions. IL-1 beta is synthetized as biologically inactive 35 kDa cytosolic precursor. Processing of bioactive IL-1 beta depends on activation of caspase-1 by protein complexes termed the inflammasomes. Most of the IL-1 beta remains intracellular; an additional signal such as ATP is needed for its secretion. Even low concentrations of IL-1 beta cause fever, hypotension and production of additional proinflammatory chemokines/cytokines, such as IL-6. IL-1 beta exerts biological effects by binding the membrane-bound type I IL-1 receptor (IL-1R), which then associates with the IL-1-receptor accessory protein (IL-1RAcP) to form a complex capable of intracellular signaling. This signalling controls expression of a number of inflammatory and catabolic genes. Besides its favorable role in mediating host responses to microbial invasion, IL-1 beta has also harmful effects. IL-1 beta can promote tumor invasiveness, tumor angiogenesis and metastasis. IL-1 beta also exacerbates damage during chronic diseases and acute tissue injury. Overexpression of IL-1 beta was observed in the pathophysiological changes that occur during different diseases, such as rheumatoid arthritis, neuropathic pain, inflammatory bowel disease, osteoarthritis, multiple sclerosis and neurodegenerative diseases. It was observed that IL-1 beta impairs insulin-producing Beta-cell function. Macrophage-derived IL-1 beta production in insulin-sensitive organs leads to progression of inflammation and induction of insulin resistance in obesity. Regarding other biofluids, it was found that IL-1 beta is one of the most abundant cytokine in saliva. It was observed that salivary level of IL-1 beta was higher in the patients with periodontitis compared to periodontally healthy subjects.

References to Product

References

  • Bugianesi E, Bizzarri C, Rosso C, Mosca A, Panera N, Veraldi S, Dotta A, Giannone G, Raponi M, Cappa M, Alisi A, Nobili V. Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol. 2017 May 30. doi: 10.1038/ajg.2017.140. [Epub ahead of print] PubMed PMID: 28555633.
References to Summary

References to Interleukin-1 beta

  • Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005 Aug;5 (8):629-40
  • Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep;25 (3):387-408
  • Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004 Apr;3 (4):330-9
  • Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008 Jan;4 (1):34-42
  • Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50
  • Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998 Sep 29;856:1-11
  • Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87 (6):2095-147
  • Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004 Aug;4 (4):378-85
  • Eder C. Mechanisms of interleukin-1beta release. Immunobiology. 2009;214 (7):543-53
  • Gursoy UK, Kononen E, Uitto VJ, Pussinen PJ, Hyvarinen K, Suominen-Taipale L, Knuuttila M. Salivary interleukin-1beta concentration and the presence of multiple pathogens in periodontitis. J Clin Periodontol. 2009 Nov;36 (11):922-7
  • Korherr C, Hofmeister R, Wesche H, Falk W. A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. Eur J Immunol. 1997 Jan;27 (1):262-7
  • Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev. 2011 Aug;22 (4):189-95
  • Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther. 2009 Sep;9 (9):1177-88
  • Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ. Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum. 1985 Sep;28 (9):1039-46
  • Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy. 1985 Aug;40 (6):424-9
  • Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010 Feb 26;6 (2):e1000661
  • Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014 Jan;10 (1):44-56
  • Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992 Apr 30;356 (6372):768-74
  • Tobon-Arroyave SI, Jaramillo-Gonzalez PE, Isaza-Guzman DM. Correlation between salivary IL-1beta levels and periodontal clinical status. Arch Oral Biol. 2008 Apr;53 (4):346-52
Related Products Documents